drugset / Trial / NCT01400516

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

NCT01400516

RandomizedParallel-groupOpen-labelTreatment

Summary

Summary: The investigators propose a randomized controlled open label study of teriparatide in men or women with rheumatoid arthritis and joint erosions. Specifically, the investigators will examine whether teriparatide in combination with a biologic can retard the development of joint erosions. The study will be conducted at Brigham and Women's Hospital Arthritis Center, several Brigham and Women's Hospital Arthritis Center satellite practices, the University of Massachusetts Medical Center, and Massachusetts General Hospital. Hypothesis: The investigators hypothesize that the combination of teriparatide with biologic will be much more effective at retarding erosion progression then a biologic alone.

Timeline

Start
2011-08
Primary completion
2015-07-30
Completion
2016-07-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic 20 ug Subcutaneous
Background Adalimumab Monoclonal antibody
Background Calcium carbonate Other / unclassified 1000 mg
Background Etanercept Protein / enzyme biologic
Background Vitamin D Other / unclassified 800 iu

Indications